Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

• Main Authors: Jennifer E. Sager (Author), Asma El‐Zailik (Author), Julie Passarell (Author), Stefan Roepcke (Author), Xiaobin Li (Author), Melissa Aldinger (Author), Ahmed Nader (Author), Andrew Skingsley (Author), Elizabeth L. Alexander (Author), Wendy W. Yeh (Author), Erik Mogalian (Author), Chad Garner (Author), Amanda Peppercorn (Author), Adrienne E. Shapiro (Author), Maribel Reyes (Author)
• Format: Book
• Published: Wiley, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to moderate coronavirus disease 2019 following either intravenous (i.v.) or intramuscular (i.m.) administration. Popu...